Compare INVZ & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVZ | VNDA |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.5M | 289.0M |
| IPO Year | N/A | 2006 |
| Metric | INVZ | VNDA |
|---|---|---|
| Price | $1.30 | $6.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.10 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 5.0M | 1.1M |
| Earning Date | 11-12-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $48,442,000.00 | ★ $212,074,000.00 |
| Revenue This Year | $146.75 | $12.01 |
| Revenue Next Year | $53.30 | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.09 | 11.12 |
| 52 Week Low | $0.48 | $3.81 |
| 52 Week High | $3.14 | $6.32 |
| Indicator | INVZ | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 67.40 |
| Support Level | $1.24 | $4.89 |
| Resistance Level | $1.38 | $6.32 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 59.62 | 83.49 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.